GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (OTCPK:AVHHL) » Definitions » 12-1 Month Momentum %

AVHHL (AVITA Medical) 12-1 Month Momentum % : -28.52% (As of Dec. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-15), AVITA Medical's 12-1 Month Momentum % is -28.52%.

The industry rank for AVITA Medical's 12-1 Month Momentum % or its related term are showing as below:

AVHHL's 12-1 Month Momentum % is ranked better than
66.39% of 842 companies
in the Medical Devices & Instruments industry
Industry Median: -12.26 vs AVHHL: -28.52

Competitive Comparison of AVITA Medical's 12-1 Month Momentum %

For the Medical Devices subindustry, AVITA Medical's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical's 12-1 Month Momentum % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where AVITA Medical's 12-1 Month Momentum % falls into.



AVITA Medical  (OTCPK:AVHHL) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVITA Medical  (OTCPK:AVHHL) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


AVITA Medical 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of AVITA Medical's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


AVITA Medical Business Description

Traded in Other Exchanges
Address
28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.